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Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic
t(9;14)(q34;q32)
Kim De Keersmaecker, Carlos Graux, Maria D. Odero, Nicole Mentens, Riet Somers, Johan Maertens, Iwona Wlodarska,
Peter Vandenberghe, Anne Hagemeijer, Peter Marynen, and Jan Cools
The BCR-ABL1 fusion kinase is frequently
associated with chronic myeloid leukemia
and B-cell acute lymphoblastic leukemia but
is rare in T-cell acute lymphoblastic leuke-
mia (T-ALL). We recently identified NUP214-
ABL1 as a variant ABL1 fusion gene in 6% of
T-ALL patients. Here we describe the identi-
fication of another ABL1 fusion, EML1-
ABL1, in a T-ALL patient with a cryptic
t(9;14)(q34;q32) associated with deletion of
CDKN2A (p16) and expression of TLX1
(HOX11). Echinoderm microtubule-associ-
ated protein–like 1–Abelson 1 (EML1-ABL1)
is a constitutively phosphorylated tyrosine
kinase that transforms Ba/F3 cells to growth
factor–independent growth through activa-
tion of survival and proliferation pathways,
including extracellular signal-related kinase
1/2 (Erk1/2), signal transducers and activa-
tors of transcription 5 (Stat5), and Lyn ki-
nase. Deletion of the coiled-coil domain of
EML1 abrogated the transforming proper-
ties of the fusion kinase. EML1-ABL1 and
breakpoint cluster region (BCR)–ABL1 were
equally sensitive to the tyrosine kinase inhib-
itor imatinib. These data further demon-
strate the involvement of ABL1 fusions in
the pathogenesis of T-ALL and identify
EML1-ABL1 as a novel therapeutic target of
imatinib. (Blood. 2005;105:4849-4852)
© 2005 by The American Society of Hematology
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is frequently character-
ized by chromosomal rearrangements leading to ectopic expression of
transcription factors (including TLX1, TLX3, LMO1, LYL1) or the
generation of chimeric transcription factors (including SIL-TAL1 or
MLL fusions).1,2 In addition, mutations in protein tyrosine kinases (LCK
and FLT3) have also been identified in a small subset of T-ALL cases.3,4
In contrast to B-cell acute lymphoblastic leukemia (B-ALL), the
BCR-ABL1 oncogene is only rarely implicated in the pathogenesis
of T-ALL1,5-7 but we recently identified a variant ABL1 fusion gene,
NUP214-ABL1, in approximately 6% of T-ALL patients.8 NUP214-
ABL1 was highly associated with ectopic expression of TLX1 or
TLX3 and deletion of CDKN2A.8 Here we report the identification
and characterization of EML1-ABL1, another variant ABL1 fusion
gene that is generated by the t(9;14)(q34;q32), which is not
detectable by standard cytogenetics.
Study design
Patients
A total of 116 T-ALL patients were screened for ABL1 rearrangements. The
16-year-old female patient with a cryptic t(9;14) presented with very high
leukocytosis (455  109/L), with 99% blasts with the phenotype of cortical
thymocytes, and normal karyotype. She is in first complete
remission 15 months after diagnosis. This study was approved by the
Ethical Committee of the Medical Faculty of the University of Leuven.
Informed consent was obtained from all subjects.
FISH
Fluorescence in situ hybridization (FISH) was performed using standard
protocols. Metaphases were hybridized up to 3 times9 using the LSI
BCR-ABL ES (Vysis, Downers Grove, IL) translocation probe or bacterial
artificial chromosome (BAC) probes RP11-57C19 and RP11-83J21
(BACPAC Resources, Oakland, CA).
RACE and PCR
The 5–rapid amplification of cDNA ends (5-RACE) polymerase chain
reaction (PCR) was performed as described previously.10 Synthesis of
cDNA was performed with the ABL1-R1 primer (5-gcgtgatgtagttgcttg),
followed by PCR with the RACE primers and the nested ABL1 primers
ABL1-R2 (5-acaccattccccattgtgattat) and ABL1-R3 (5-ccggagcttttcacctt-
tagtta). The presence of the EML1-ABL1 fusion transcript was confirmed by
reverse transcriptase–PCR (RT-PCR) using the primers EML1-F (5-
cactcactgggaggtggttt) and ABL1-R2. EML1 expression was detected using
primers EML1-F (5-tagaatagatctcgcgatggcactgtgttaccaaag) and EML1-R
(5-caatgtcacagaatcccagatg). ZNF384 was amplified as described previ-
ously.8 Detection of TLX1, TLX2, TLX3, and NKX2-5 expression was
performed as described.11
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Constructs
The open reading frame of exon 1 to 17 of EML1 was amplified from an
IMAGE clone (accession no. BC033043) with primers EML1-F1 (5-
ggaaagatctcagcatggaggacggcttct) and EML1-R (5-tagaatgcggccgctctggtgag-
tatcgcattacag). EML1 in which nucleotides 1 to 363 of the open reading
frame were deleted (del EML1) was obtained by replacement of EML1-F1
by the EML1-F2 primer (5-ggaaagatctcagcatggctgtgccagcaaccaaaag). The
ABL1 part was amplified from a BCR-ABL construct, using primers
ABL1-F (5-tagaatgcggccgctagcatctga) and ABL1-R (5-tagaatgaattctacctct-
gcactatgtcact). The generated EML1/del EML1 parts were ligated together
with the ABL1 fragment in the retroviral vector murine stem cell
virus–puromycin (MSCV-puro; Clontech, Palo Alto, CA).
Cell culture and retroviral transduction
HEK 293T and Ba/F3 cells were cultured, transfected, and transduced as
described previously.12 Transduced Ba/F3 cells were selected with puromy-
cin (2.5 g/mL) or neomycin (600 g/mL medium). For Western blotting,
Ba/F3 cells were incubated with imatinib for 90 minutes. For growth
curves, 105 Ba/F3 cells were seeded in 1 mL medium and viable cells were
counted on 3 consecutive days. For dose-response curves, 2  105 Ba/F3
cells were seeded in 1 mL medium and incubated in the presence of imatinib
for 24 hours. Viable cell numbers were determined with the AQueousOne
Solution (Promega, Madison, WI).
Western blotting
Total cell lysates were analyzed by standard procedures using the following
antibodies: anti–phospho-ABL1 (Tyr412), anti-ABL1, anti-phospho–
extracellular signal-related kinase 1/2 (anti–phospho-ERK1/2; Thr202/
Tyr204), and anti-phospho–severe combined immunodeficiency repopulat-
ing cell (anti–phospho-SRC) family (Tyr 416; Cell Signaling, Beverly,
MA); anti-ERK2, anti-phospho–signal transducers and activators of tran-
scription 5 (anti–phospho-STAT5), anti-STAT5a, and anti-LYN (Santa Cruz
Biotechnology, Santa Cruz, CA); antiphosphotyrosine (4G10; Upstate
Biotechnology, Lake Placid, NY); and antimouse/antirabbit peroxidase-
labeled antibodies (AP Biotech, Uppsala, Sweden).
Results and discussion
In the process of screening 116 T-ALL patients for ABL1 gene
rearrangements by FISH, we detected 6 cases with ABL1 amplifica-
tion (5 were recently reported),8 1 case with inv(9), and 1 case with
a cryptic translocation t(9;14)(q34;q32). Further investigation of
the t(9;14) case confirmed that the breakpoint was in intron 1 of
ABL1 (Figure 1A). RACE experiments revealed that the t(9;14)
generated an in-frame fusion between exon 17 of EML1 (echino-
derm microtubule-associated protein–like 1 gene) and exon 2 of
ABL1 (Figure 1E).
EML1 was mapped within the Usher syndrome type 1a locus on
14q32 and encodes a protein with high similarity to the echinoderm
microtubule-associated protein.13 Unlike other fusion partners of
ABL1, EML1 seems to have a more restricted expression pattern,13
and we could not detect its expression in T-ALL cases or cell lines
without the t(9;14) (Figure 1D). This suggests that activity of the
EML1 promoter in the leukemic cells with the t(9;14) could be a
consequence of the translocation.
The EML1-ABL1 fusion gene results in the formation of a
190-kDa EML1-ABL1 protein containing the coiled-coil domain
of EML1 and the kinase domain of ABL1 (Figure 1E). RT-PCR
confirmed the EML1-ABL1 fusion transcript in the patient with
t(9;14) (Figure 1D). Further molecular analysis of this case also revealed
hemizygous deletion of the tumor suppressor gene CDKN2A (Figure
1B) as well as ectopic expression of the homeobox gene TLX1 (Figure
1C), 2 known oncogenic events in T-ALL.1,2
To investigate the oncogenic potential of EML1-ABL1, the
fusion gene (as it was identified in the patient) and a variant in
which the coiled-coil domain of EML1 was deleted (del EML1-
ABL1) were expressed in the interleukin 3 (IL3)–dependent Ba/F3
cell line. EML1-ABL1 expression transformed the Ba/F3 cells to
IL3-independent growth, but cells expressing del EML1-ABL1
were not transformed and died upon IL3 withdrawal (Figure 2A).
Western blot analysis confirmed that both EML1-ABL1 and del
EML1-ABL1 were expressed but only EML1-ABL1 was tyrosine
phosphorylated. (Figure 2B). In addition, only Ba/F3 cells expressing
EML1-ABL1 showed phosphorylation of Erk1/2 and Stat5 (Figure 2B).
These observations demonstrate that the coiled-coil domain of EML1 is
required for activation of EML1-ABL1, similar to what was shown for
Figure 1. Identification of t(9;14)(q34;q32) and detection of EML1-ABL1 and
TLX1 expression. (A) FISH with 5 ABL1 (green signal) and 3 ABL1 (red signal)
probes on metaphase cells of the T-ALL patient with the cryptic t(9;14)(q34;q32). The
translocation causes separation of the 2 probes with the 5 ABL1 probe hybridizing to
der(9) and the 3 ABL1 probe hybridizing to der(14). (B) FISH with CDKN2A probe
(red signal) and chromosome 9 centromere probe (green signal) on interphase cells
of the patient with t(9;14)(q34;q32). The absence of a second red signal in each cell is
caused by hemizygous CDKN2A deletion. FISH data were collected on a Leica
DMRB (Wetzlar, Germany) fluorescence microscope equipped with a triple band-
pass filter and a cooled black and white charged couple device camera (Photomet-
rics, Tuscon, AZ) run by Quips SmartCapture FISH Imaging Software (Vysis,
Downers Grove, IL). (C) Detection of TLX1 transcripts in the patient with t(9;14) by
RT-PCR. TLX2, TLX3, or NKX2-5 transcripts were not detected in this patient. (D;
Left) RT-PCR detection of the EML1-ABL1 fusion transcript in the patient with t(9;14)
(patient 1) and absence of these fusion transcripts in 3 other T-ALL patients (patients 2-4).
(Right) RT-PCR analysis of EML1 expression in the 4 patient samples analyzed in the left
part of the figure and in 4 T-ALL cell lines. ZNF384 was amplified as a control of RNA
quality. (E) Schematic representation of the EML1,ABL1, and EML1-ABL1 fusion proteins.
The sequence of the in-frame fusion between exon 17 of EML1 and exon 2 of ABL1 is
indicated at the bottom. SH3 indicates Src homology 3.
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the dimerization domain of ETV6 in the context of ETV6-ABL1.14 The
importance of the coiled-coil domain in the context of BCR-ABL1
isless clear for transformation in vitro but is well demonstrated for its in
vivo oncogenic properties.15,16
We next tested the sensitivity of EML1-ABL1 to imatinib, a
selective inhibitor of ABL1 kinase activity.17 Imatinib concentra-
tions required to inhibit proliferation of the EML1-ABL1– and
BCR-ABL1–transformed Ba/F3 cells were comparable (50% inhibi-
tory concentration [IC50] 0.2 M; Figure 2C). The effect of
imatinib on EML1-ABL1–expressing Ba/F3 cells was assessed
using an antiphosphotyrosine antibody. This confirmed that the
major phosphorylated proteins were EML1-ABL1, Stat5, and Lyn
and that phosphorylation of these proteins decreased with increas-
ing dose of imatinib (Figure 2D). The phosphorylation status of
Lyn, a recently identified critical downstream effector of BCR-
ABL1 in B-ALL,18,19 was also determined by immunoprecipitation
followed by detection of its phosphorylation on Tyr396 (Figure
2D). This confirmed decreased activity of Lyn upon imatinib
treatment of the EML1-ABL1–expressing Ba/F3 cells.
Taken together, our data identify EML1-ABL1 as a constitu-
tively activated tyrosine kinase most likely implicated in the
pathogenesis of T-ALL that is similar to BCR-ABL1 in its mode of
activation, its activated signaling pathways, and its sensitivity to
imatinib.20,21 It remains to be investigated whether the cryptic
t(9;14)(q34;q32) accounts for a number of atypical chronic my-
eloid leukemia cases or BCR-ABL1–negative imatinib responsive
myeloproliferative diseases.12,22 The association of EML1-ABL1
with ectopic expression of TLX1 and deletion of CDKN2A is
consistent with a multistep pathogenesis of T-ALL. This study
further demonstrates the involvement of variant ABL1 fusion genes
in the pathogenesis of T-ALL and provides another example of an
imatinib-sensitive fusion kinase.
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